foto
LATEST NEWS

 OctoPlus announces 2010 first half-year results



WEBCAST HALF-YEAR RESULTS

Click here to access the webcast of 6 August 2010



OCTOPLUS OPENED NYSE EURONEXT

In celebration of OctoPlus' 15 year anniversday, CEO Simon Sturge and CFO Susan Swarte opened the financial markets in Amsterdam on Tuesday 27 July



OCTOPLUS ANNUAL REPORT 2009
VIEW OUR WEB SEMINARS
OCTO SHARE PRICE
HOME dashNL dash CONTACT

 

OVERVIEW

Contract pharmaceutical development and clinical trial material manufacturing

Founded in 1995, OctoPlus has built up a wealth of expertise in the pharmaceutical development of conventional and biotech-derived pharmaceuticals.

OctoPlus develops dosage forms enabling the administration of new medicines to patients. We cover this process from lab bench to clinical batches.

We have helped our partners bring more than 40 products into the clinic or to the market and are globally recognized as a center of excellence in formulation development, analytical services and small scale cGMP manufacturing.

All OctoPlus work is performed in our dedicated facilities in the Bioscience Park in Leiden, the Netherlands, where we operate a cGMP production area with dedicated areas for filling and finishing of sterile dosage forms. Our facilities comply with EU and FDA regulations and are regularly audited by our partners.